US Pharma MarketingThe post Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial appeared first on Clinical Trials Arena.
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients. Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients. Arrowhead announced the Phase I/IIa data for its RNAi therapy. Credit: Antonio Marca / Shutterstock.com Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a Phase I/IIa trial. The study (NCT07221344) has provided clinical validation of the candidate, dubbed ARO-MAPT, to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain. LOA and PTSR Model ACU-193…
Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients.
Source: Clinical Trials Arena